CA3194325A1 - Lipid nanoparticles for delivering mrna vaccines - Google Patents

Lipid nanoparticles for delivering mrna vaccines

Info

Publication number
CA3194325A1
CA3194325A1 CA3194325A CA3194325A CA3194325A1 CA 3194325 A1 CA3194325 A1 CA 3194325A1 CA 3194325 A CA3194325 A CA 3194325A CA 3194325 A CA3194325 A CA 3194325A CA 3194325 A1 CA3194325 A1 CA 3194325A1
Authority
CA
Canada
Prior art keywords
mrna
composition
lnp
lipid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3194325A
Other languages
English (en)
French (fr)
Inventor
Danilo Casimiro
Sudha CHIVUKULA
Frank Derosa
Anusha DIAS
Rebecca L. Goldman
Hardip Rajeshbhai GOPANI
Kirill Kalnin
Shrirang KARVE
Asad KHANMOHAMMED
Priyal PATEL
Timothy PLITNIK
Ashish L. SARODE
Timothy TIBBITTS
Khang Anh TRAN
Natalia VARGAS MONTOYA
Angela Lynne BEAULIEU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi SA
Original Assignee
Sanofi SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi SA filed Critical Sanofi SA
Priority claimed from PCT/US2021/058250 external-priority patent/WO2022099003A1/en
Publication of CA3194325A1 publication Critical patent/CA3194325A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA3194325A 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines Pending CA3194325A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063110965P 2020-11-06 2020-11-06
US63/110,965 2020-11-06
US202163212523P 2021-06-18 2021-06-18
US63/212,523 2021-06-18
EP21315198.8 2021-10-13
EP21315198 2021-10-13
PCT/US2021/058250 WO2022099003A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Publications (1)

Publication Number Publication Date
CA3194325A1 true CA3194325A1 (en) 2022-05-12

Family

ID=86184333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3194325A Pending CA3194325A1 (en) 2020-11-06 2021-11-05 Lipid nanoparticles for delivering mrna vaccines

Country Status (9)

Country Link
EP (1) EP4240335A1 (enExample)
JP (2) JP7817257B2 (enExample)
KR (1) KR20230104223A (enExample)
CN (1) CN116406299A (enExample)
AU (1) AU2021374976A1 (enExample)
CA (1) CA3194325A1 (enExample)
CO (1) CO2023005218A2 (enExample)
IL (1) IL302631A (enExample)
MX (1) MX2023005203A (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024097874A1 (en) * 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
WO2024098491A1 (zh) * 2022-11-11 2024-05-16 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2024098498A1 (zh) * 2022-11-11 2024-05-16 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
US12208288B2 (en) 2015-10-22 2025-01-28 Modernatx, Inc. Betacoronavirus RNA vaccines
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna
US12453766B2 (en) 2018-01-29 2025-10-28 Modernatx, Inc. RSV RNA vaccines

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022294274A1 (en) * 2021-06-18 2024-02-01 Sanofi Pasteur Inc. Multivalent influenza vaccines
CN122422511A (zh) * 2023-10-31 2026-07-17 仁景(苏州)生物科技有限公司 一种多价流感mRNA疫苗
CN120053395A (zh) * 2023-11-30 2025-05-30 苏州维益生物科技有限公司 含二硫键的核酸-脂质颗粒、药物、用途、及制备方法
CN118725043B (zh) * 2024-06-27 2025-12-05 中国人民解放军陆军军医大学 用于递送核酸的多肽-脂质组合物及其应用和mRNA疫苗
CN121265551A (zh) * 2024-07-02 2026-01-06 苏州星核迪赛生物技术有限公司 一种靶向肝实质细胞的核酸递送载体及其应用
WO2026095067A1 (ja) * 2024-11-01 2026-05-07 Ａｇｃ株式会社 核酸送達用脂質ナノ粒子
CN119746089B (zh) * 2025-03-07 2025-06-13 细胞生态海河实验室 脂质纳米颗粒冷冻保护剂
CN121466311A (zh) * 2026-01-09 2026-02-06 羿美诚健(上海)生物医药有限公司 一种脂质组合物及其在核酸递送中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3122878T3 (pl) * 2014-03-24 2019-06-28 Translate Bio, Inc. TERAPIA mRNA DO LECZENIA CHORÓB OCZU
RS64331B1 (sr) * 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
TW202309002A (zh) * 2021-04-15 2023-03-01 美商轉譯生技公司 基於「古德」緩衝液的陽離子脂質

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12150980B2 (en) 2015-07-30 2024-11-26 Modernatx, Inc. Concatemeric peptide epitope RNAs
US12403336B2 (en) 2015-10-22 2025-09-02 Modernatx, Inc. Betacorona virus mRNA vaccines
US12208288B2 (en) 2015-10-22 2025-01-28 Modernatx, Inc. Betacoronavirus RNA vaccines
US12403335B2 (en) 2015-10-22 2025-09-02 Modernatx, Inc. Betacoronavirus MRNA vaccines
US12409347B2 (en) 2015-10-22 2025-09-09 Modernatx, Inc. Betacoronavirus mRNA vaccines
US12521577B2 (en) 2015-10-22 2026-01-13 Modernatx, Inc. Betacoronavirus RNA vaccines
US12551734B2 (en) 2015-10-22 2026-02-17 Modernatx, Inc. Betacoronavirus mRNA vaccines
US12629412B2 (en) 2015-10-22 2026-05-19 Modernatx, Inc. Betacoronavirus mRNA vaccines
US12453766B2 (en) 2018-01-29 2025-10-28 Modernatx, Inc. RSV RNA vaccines
WO2024097874A1 (en) * 2022-11-03 2024-05-10 Modernatx, Inc. Chemical stability of mrna
WO2024098498A1 (zh) * 2022-11-11 2024-05-16 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2024098491A1 (zh) * 2022-11-11 2024-05-16 深圳先进技术研究院 一种编码抗禽流感H7N9病毒抗体的mRNA及其制法和应用
WO2025054383A1 (en) * 2023-09-06 2025-03-13 Modernatx, Inc. Chemical stability of mrna

Also Published As

Publication number Publication date
IL302631A (en) 2023-07-01
JP7817257B2 (ja) 2026-02-18
MX2023005203A (es) 2023-07-13
JP2026089059A (ja) 2026-05-29
AU2021374976A1 (en) 2023-06-29
KR20230104223A (ko) 2023-07-07
CN116406299A (zh) 2023-07-07
CO2023005218A2 (es) 2023-05-19
JP2023550600A (ja) 2023-12-04
EP4240335A1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
US12239735B2 (en) Lipid nanoparticles for delivering mRNA vaccines
JP7817257B2 (ja) ｍＲＮＡワクチンを送達するための脂質ナノ粒子
US20230043128A1 (en) Multivalent influenza vaccines
US20230302112A1 (en) Respiratory synctial virus rna vaccine
JP7848141B2 (ja) 核酸ベースの混合ワクチン
AU2022399571A1 (en) Human metapneumovirus vaccines
WO2025003756A2 (en) Multivalent influenza mrna vaccines
WO2025051975A1 (en) Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
CN117580568A (zh) 多价流感疫苗
AU2024268214A1 (en) Combination respiratory mrna vaccines
JP2026500282A (ja) インフルエンザウイルス様粒子をコードするｍＲＮＡ
RU2860421C2 (ru) ЛИПИДНЫЕ НАНОЧАСТИЦЫ ДЛЯ ДОСТАВКИ mRNA-ВАКЦИНЫ
HK40096671A (en) Lipid nanoparticles for delivering mrna vaccines
WO2024131726A1 (zh) 一种广谱流感mRNA疫苗
WO2025227110A2 (en) Multivalent antigens

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241022

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241022

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241022

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20250425

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250425

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250530

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20251021

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251021

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251021

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260126

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260212

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260212

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260316

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260316

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260316

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728